Moderna sees Taiwan as a crucial site for clinical trials necessary for refining its mRNA technology, and will include it as a site for its multicenter trials, said Patrick Bergstedt, a senior vice president of Moderna, on Tuesday during his first visit to the country.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
KMT Yilan official receives 18 months for recall campaign fraud
07/14/2026 08:51 PM - Science & Tech
Stool blood levels may help tailor colonoscopy follow-up: NTUH study
07/14/2026 08:42 PM - Business
Taiwan's overseas investment surges 58% in 5 years
07/14/2026 08:32 PM - Politics
Subsidized China trip for Taiwan teachers carries 'united front' risk: MAC
07/14/2026 08:18 PM - Politics
Opposition fast-tracks referendum proposals on nuclear policy, euthanasia
07/14/2026 07:52 PM